Shares of Assembly Biosciences Inc. (ASMB) have surged more than 60% over the past month, driven by investor optimism ahead of multiple clinical data readouts expected in the coming months.
The company's lead drug candidate is ABI-4334, an orally bioavailable, next-generation capsid assembly modulator being developed for the treatment of chronic hepatitis B virus (HBV) infection - a disease that affects approximately 254 million people globally.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.